Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Study to Assess the Efficacy and Tolerability of MK-0364 (taranabant) in Maintaining Diet-Induced Weight Loss in Obese Patients
2006-004366-14Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing taranabant with placebo (2 arms). Primary endpoint: Body Weight. Started Sep 2006; status: terminated.
02
Drugs
taranabant
03
Conditions
obesity
Beyond the preview
Go deeper on 2006-004366-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004366-14.